Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study DOI Creative Commons
Bing Xie, Nan Ye, Guoqin Wang

et al.

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: April 28, 2025

The renal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been confirmed. However, SGLT2i may lead to an increase in serum creatine shortly after administration. This study explores the factors influencing this change and its impact on long-term function. We retrospectively studied patients starting treatment, classifying them into kidney function deterioration (RD) non-deterioration (non-RD) groups based three-month creatinine changes. Multivariate logistic regression identified RD, mixed-effects linear models evaluated eGFR slope A total 544 were included, with 78 (14.3%) RD group 466 (85.7%) non-RD group. Lower albumin are independent risk for RD. With decrease by 10 mL/min/1.73㎡, increased 42.3% (p < .001). 5 g/L, 41.7% maximum difference between was 13.88 mL/min/1.73 m2 (95%CI, 9.99 17.78; p .001) two months. One year medication, not related whether occurred ≥ .05). During first three months post-medication, 40.51 per 27.43 53.60; Over years, 0.59 -0.69 1.88; > While some experiences creatine, there is no significant groups.

Language: Английский

Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study DOI Creative Commons
Bing Xie, Nan Ye, Guoqin Wang

et al.

Renal Failure, Journal Year: 2025, Volume and Issue: 47(1)

Published: April 28, 2025

The renal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been confirmed. However, SGLT2i may lead to an increase in serum creatine shortly after administration. This study explores the factors influencing this change and its impact on long-term function. We retrospectively studied patients starting treatment, classifying them into kidney function deterioration (RD) non-deterioration (non-RD) groups based three-month creatinine changes. Multivariate logistic regression identified RD, mixed-effects linear models evaluated eGFR slope A total 544 were included, with 78 (14.3%) RD group 466 (85.7%) non-RD group. Lower albumin are independent risk for RD. With decrease by 10 mL/min/1.73㎡, increased 42.3% (p < .001). 5 g/L, 41.7% maximum difference between was 13.88 mL/min/1.73 m2 (95%CI, 9.99 17.78; p .001) two months. One year medication, not related whether occurred ≥ .05). During first three months post-medication, 40.51 per 27.43 53.60; Over years, 0.59 -0.69 1.88; > While some experiences creatine, there is no significant groups.

Language: Английский

Citations

0